Skip to main content

Guggenheim Sticks to Their Buy Rating for Adicet Bio (ACET)

Tipranks - Tipranks - Wed Oct 8, 2025

Guggenheim analyst Yatin Suneja maintained a Buy rating on Adicet Bio today and set a price target of $8.00. The company’s shares closed today at $0.85.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Suneja is a 5-star analyst with an average return of 15.9% and a 54.52% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Larimar Therapeutics, Dianthus Therapeutics, and MoonLake Immunotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adicet Bio with a $5.80 average price target, implying a 579.87% upside from current levels. In a report released on October 1, JonesTrading also maintained a Buy rating on the stock with a $4.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

ACET market cap is currently $83.25M and has a P/E ratio of -0.77.

Read More on ACET:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).